Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker SNY · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Nov 13, 2026 | Study of a Combination SARS-CoV-2 Recombinant Spike and High-Dose Inactivated Influenza Vaccine Wit… NCT07890454 · Immunization, Healthy Volunteers IIV-HD (standalone), NVXC19 (EU licensed, standalone) | SNY Sanofi | Phase 3 | Recruiting was not yet recruiting | 6,000 | Dec 28, 2027 | Registry ↗ |
| Nov 13, 2026 | Study to Compare the Plasma Concentration of Belumosudil Given as an Oral Suspension and as a Table… NCT07726914 · Chronic Graft Versus Host Disease Belumosudil, Belumosudil | SNY Sanofi | Phase 1 | Not yet recruiting | 58 | Jan 26, 2027 | Registry ↗ |
| Nov 13, 2026 | Study of Different Formulations of Vaccines Encoding the RSV Monovalent Antigen or the Flu H5 Antig… NCT07516418 · Respiratory Syncytial Virus (RSV), Influenza A(H5N1) H5 Flu Investigational Medical Product (IMP) 1, H5 Flu IMP 2 | SNY Sanofi | Phase 1 | Active, not recruiting was recruiting | 360 | Apr 4, 2027 | Registry ↗ |
| Nov 13, 2026 | A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to… NCT07088068 · Type 1 Diabetes Mellitus Teplizumab, Placebo | SNY Sanofi | Phase 3 | Recruiting | 723 | Jun 6, 2028 | Registry ↗ |
| Nov 13, 2026 | A Prospective Study to Observe & Describe Clinical Outcomes of Alglucosidase Alfa Treatment in Pati… NCT04848779 · Glycogen Storage Disease Type II Alglucosidase alfa GZ419829 | SNY Sanofi | — | Completed was active, not recruiting | 9 | Oct 27, 2026 | Registry ↗ |
| Nov 12, 2026 | A Study to Investigate Long-term Safety and Tolerability of Frexalimab in Participants With Multipl… NCT07930624 · Multiple Sclerosis Frexalimab, Frexalimab | SNY Sanofi | Phase 3 | Not yet recruiting | 2,500 | May 16, 2031 | Registry ↗ |
| Nov 12, 2026 | Study of a Recombinant Spike COVID-19 Vaccine With Matrix-M in Older Adults and People at Increased… NCT07861542 · COVID-19 Omicron Subvariant-Based SARS-CoV-2 Recombinant Spike Vacci… | SNY Sanofi | Phase 4 | Active, not recruiting was recruiting | 669 | Nov 26, 2026 | Registry ↗ |
| Nov 12, 2026 | A Post-marketing Surveillance Study of Beyfortus (Nirsevimab) in Republic of Korea NCT07200206 · Respiratory Syncytial Virus Nirsevimab | SNY Sanofi | — | Recruiting | 3,000 | Sep 26, 2029 | Registry ↗ |
| Nov 12, 2026 | A Study to Investigate the Efficacy and Safety of SAR444336 in Adults With Microscopic Colitis in C… NCT07156175 · Microscopic Colitis SAR444336, Placebo | SNY Sanofi | Phase 2 | Active, not recruiting was recruiting | 60 | Apr 8, 2027 | Registry ↗ |
| Nov 12, 2026 | Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytope… NCT07007962 · Immune Thrombocytopenia rilzabrutinib | SNY Sanofi | Phase 3 | Recruiting | 60 | Nov 5, 2027 | Registry ↗ |
| Nov 12, 2026 | A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Particip… NCT06500702 · Focal Segmental Glomerulosclerosis, Glomerulonephritis Mini… frexalimab, brivekimig | SNY Sanofi | Phase 2 | Recruiting | 84 | Dec 23, 2026 | Registry ↗ |
| Nov 12, 2026 | Agalsidase Beta Long-Term Treatment Outcome for Fabry Disease Patients With IVS4 Mutation in Taiwan NCT06052800 · Fabry Disease | SNY Sanofi | — | Completed was active, not recruiting | 78 | Oct 7, 2026 | Registry ↗ |
| Nov 10, 2026 | The Efficacy and Safety of Venglustat Compared With Cerezyme in Pediatric Participants 2 to 11 Year… NCT07927140 · Gaucher's Disease Type III Venglustat, Imiglucerase | SNY Sanofi | Phase 3 | Not yet recruiting | 18 | Jan 14, 2030 | Registry ↗ |
| Nov 10, 2026 | Rilzabrutinib for the Adult Participants With Chronic ITP Who Have Completed Phase 3 Study in Japan NCT07216079 · Immune Thrombocytopenia rilzabrutinib | SNY Sanofi | Phase 3 | Active, not recruiting | 3 | Nov 25, 2026 | Registry ↗ |
| Nov 10, 2026 | A Study to Investigate Safety of Belumosudil in Participants Aged 12 Years and Above, With Chronic… NCT07135973 · Chronic Graft Versus Host Disease Belumosudil | SNY Sanofi | Phase 4 | Not yet recruiting | 26 | Aug 30, 2027 | Registry ↗ |
| Nov 9, 2026 | A Study to Investigate Efficacy and Safety of Duvakitug in Adult Participants With Moderate to Seve… NCT07812116 · Hidradenitis Duvakitug, Placebo | SNY Sanofi | Phase 2 | Recruiting was not yet recruiting | 156 | Jun 16, 2028 | Registry ↗ |
| Nov 9, 2026 | Real-World Study of Patients With Type 1 Diabetes Treated With Teplizumab as Part of Managed Access… NCT07457580 · Type 1 Diabetes Teplizumab | SNY Sanofi | — | Recruiting | 60 | Nov 30, 2026 | Registry ↗ |
| Nov 9, 2026 | Long-Term Outcomes of Teplizumab in Routine Clinical Care NCT07360080 · Type 1 Diabetes Teplizumab | SNY Sanofi | — | Recruiting | 1,000 | Oct 29, 2035 | Registry ↗ |
| Nov 9, 2026 | Efanesoctocog Alfa Prophylaxis in Patients With Hemophilia A With Synovial Hypertrophy NCT06941870 · Factor VIII Deficiency Efanesoctocog alfa | SNY Sanofi | Phase 4 | Recruiting | 35 | Oct 25, 2027 | Registry ↗ |
| Nov 9, 2026 | Efficacy and Safety of Teplizumab in Japanese Participants With Stage 2 Type 1 Diabetes NCT06791291 · Type 1 Diabetes Mellitus Teplizumab | SNY Sanofi | Phase 2 | Active, not recruiting was recruiting | 5 | Mar 6, 2028 | Registry ↗ |
| Nov 9, 2026 | Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressi… NCT06141486 · Multiple Sclerosis Frexalimab, Placebo | SNY Sanofi | Phase 3 | Active, not recruiting | 943 | Mar 24, 2028 | Registry ↗ |
| Nov 6, 2026 | An Open-label, DDI Study to Investigate the Effects of Duvakitug on the PK of Selected Cytochrome P… NCT07923383 · Ulcerative Colitis, Crohn's Disease Duvakitug | SNY Sanofi | Phase 1 | Not yet recruiting | 25 | Aug 8, 2028 | Registry ↗ |
| Nov 6, 2026 | Phase 2 and 3 Placebo Controlled & Long-term Extension Study of Rilzabrutinib in Adults With iCVID… NCT07923305 · Immunodeficiency Common Variable rilzabrutinib, placebo | SNY Sanofi | Phase 2/3 | Not yet recruiting | 96 | May 10, 2035 | Registry ↗ |
| Nov 6, 2026 | A Study to Investigate the Efficacy and Safety of Belumosudil Compared With Best Available Therapy… NCT07771439 · Chronic Graft Versus Host Disease Belumosudil, Best available therapy (BAT) | SNY Sanofi | Phase 3 | Recruiting was not yet recruiting | 356 | Sep 14, 2029 | Registry ↗ |
| Nov 6, 2026 | A Study to Investigate the Safety and Effectiveness of SAR448851 in Participants With Early Alzheim… NCT07688213 · Dementia, Alzheimer's Type, Alzheimer's Disease SAR448851, Placebo | SNY Sanofi | Phase 2 | Recruiting | 160 | Jul 31, 2029 | Registry ↗ |
| Nov 5, 2026 | Pharmacokinetics, Immunogenicity and Safety of Subcutaneous Dupilumab and Berahyaluronidase Alfa (A… NCT07919899 · Dermatitis Atopic Dupilumab coformulated with berahyaluronidase alfa, Dupilum… | SNY Sanofi | Phase 3 | Not yet recruiting | 150 | May 2, 2028 | Registry ↗ |
| Nov 5, 2026 | A Study Evaluating Disease Characteristics and Outcomes in Participants With Asthma in Routine Clin… NCT07556159 · Asthma Procedure: Investigational Procedures, Procedure: Investiga… | SNY Sanofi | — | Recruiting | 2,500 | Apr 4, 2029 | Registry ↗ |
| Nov 5, 2026 | A Phase III Control Study of the Safety and Immunogenicity of vYF in Pediatric Population NCT07103148 · Yellow Fever Immunization Yellow fever vaccine (live), Yellow fever vaccine (live) | SNY Sanofi | Phase 3 | Active, not recruiting was recruiting | 2,440 | Nov 28, 2026 | Registry ↗ |
| Nov 3, 2026 | Phase 2 Study of SAR444656 in Adult Participants With Moderate to Severe Atopic Dermatitis NCT06058156 · Atopic Dermatitis SAR444656 (KT-474), Placebo | SNY Sanofi | Phase 2 | Terminated | 70 | Oct 23, 2025 | Registry ↗ |
| Nov 2, 2026 | This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic De… NCT07290803 · Atopic Dermatitis | SNY Sanofi | — | Recruiting | 1,000 | Jan 30, 2034 | Registry ↗ |
| Nov 2, 2026 | A Study to Investigate the Efficacy and Safety of Brivekimig in Adult Participants With Ulcerative… NCT06975722 · Ulcerative Colitis SAR442970, Placebo | SNY Sanofi | Phase 2 | Active, not recruiting | 105 | Dec 17, 2026 | Registry ↗ |
| Nov 2, 2026 | A Study to Investigate Efficacy and Safety of Brivekimig in Participants With Crohn's Disease NCT06958536 · Crohn's Disease brivekimig, Placebo | SNY Sanofi | Phase 2 | Recruiting | 99 | Dec 17, 2026 | Registry ↗ |
| Nov 2, 2026 | Phase 1 Study of Chlamydia Trachomatis mRNA Vaccine in Adults. NCT06891417 · Chlamydia Trachomatis Immunization Chlamydia mRNA Vaccine, Placebo | SNY Sanofi | Phase 1 | Recruiting | 80 | Nov 3, 2027 | Registry ↗ |
| Nov 2, 2026 | Frexalimab in Preservation of Endogenous Insulin Secretion Compared to Placebo in Adults and Adoles… NCT06111586 · Type 1 Diabetes Mellitus Frexalimab, Placebo | SNY Sanofi | Phase 2 | Active, not recruiting | 197 | Apr 28, 2027 | Registry ↗ |
| Oct 30, 2026 | A Retrospective Cohort Study Evaluating Major Adverse Cardiovascular Events and Cardiovascular Outc… NCT07906132 · Atherosclerotic Cardiovascular Disease | SNY Sanofi | — | Completed | 93,000 | Jul 11, 2026 | Registry ↗ |
| Oct 29, 2026 | A Study to Investigate Dupixent/ Dupilumab in Adult Indian Participants With Moderate-to-severe Ato… NCT07905547 · Atopic Dermatitis Dupilumab | SNY Sanofi | Phase 4 | Not yet recruiting | 56 | Feb 7, 2027 | Registry ↗ |
| Oct 29, 2026 | A Retrospective Cohort Study Evaluating Major Adverse Cardiovascular Events and Cardiovascular Outc… NCT07905534 · Atherosclerotic Cardiovascular Disease | SNY Sanofi | — | Active, not recruiting | 18,000 | Aug 21, 2026 | Registry ↗ |
| Oct 29, 2026 | A Retrospective Cohort Study Evaluating Major Adverse Cardiovascular Events and Cardiovascular Outc… NCT07905508 · Atherosclerotic Cardiovascular Disease | SNY Sanofi | — | Completed | 180,000 | Jun 30, 2026 | Registry ↗ |
| Oct 29, 2026 | Pharmacokinetics and Tolerability of Subcutaneous Dupilumab Coformulated With Berahyaluronidase Alf… NCT07646548 · Healthy Volunteers Dupilumab coformulated with berahyaluronidase alfa, Dupilum… | SNY Sanofi | Phase 1 | Completed was active, not recruiting | 40 | Sep 30, 2026 | Registry ↗ |
| Oct 28, 2026 | A Study to Investigate the Efficacy and Safety of Rilzabrutinib in Adult Participants With Graves'… NCT06984627 · Graves' Disease Rilzabrutinib dose 1, Rilzabrutinib dose 2 | SNY Sanofi | Phase 2 | Recruiting | 30 | Feb 11, 2027 | Registry ↗ |
| Oct 28, 2026 | Long-term Safety and Efficacy Evaluation of Lunsekimig in Adult Participants With Chronic Rhinosinu… NCT06914908 · Chronic Rhinosinusitis With Nasal Polyps Lunsekimig, Mometasone furoate nasal spray (MFNS) | SNY Sanofi | Phase 2 | Active, not recruiting | 71 | Feb 22, 2029 | Registry ↗ |
| Oct 28, 2026 | A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic… NCT06082037 · Lung Transplant Rejection Belumosudil, Azithromycin | SNY Sanofi | Phase 3 | Recruiting | 180 | Jan 29, 2029 | Registry ↗ |
| Oct 28, 2026 | Pompe Disease Registry Protocol NCT00231400 · Glycogen Storage Disease Type II, Pompe Disease | SNY Genzyme, a Sanofi Company | — | Recruiting | 2,000 | Jan 31, 2034 | Registry ↗ |
| Oct 27, 2026 | A Study to Describe Multiple Sclerosis Patients Treated With Tolebrutinib as Per Label in a Real-wo… NCT07898371 · Multiple Sclerosis Tolebrutinib | SNY Sanofi | — | Recruiting | 3,000 | Sep 21, 2031 | Registry ↗ |
| Oct 27, 2026 | SAR447971 First-in-human Study NCT07629336 · Hidradenitis, Healthy Volunteers SAR447971, Placebo | SNY Sanofi | Phase 1 | Recruiting | 122 | Apr 17, 2028 | Registry ↗ |
| Oct 27, 2026 | A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1… NCT07285460 · Hemophilia Fitusiran, Clotting factor concentrates (CFC) or bypassing… | SNY Sanofi | Phase 3 | Recruiting | 85 | Aug 4, 2029 | Registry ↗ |
| Oct 27, 2026 | Long-term Safety and Efficacy Study of Riliprubart in Participants With CIDP NCT06859099 · Polyneuropathy, Inflammatory Demyelinating, Chronic Riliprubart Prefilled Pen (PFP) | SNY Sanofi | Phase 3 | Enrolling by invitation | 300 | Oct 3, 2029 | Registry ↗ |
| Oct 26, 2026 | A Study to Describe Patient REal-world FitusiRan ExpeRience NCT07895381 · Hemophilia A or B | SNY Sanofi | — | Not yet recruiting | 100 | Mar 2, 2029 | Registry ↗ |
| Oct 26, 2026 | A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexametha… NCT06356571 · Plasma Cell Myeloma Refractory Isatuximab SC-OBDS, Montelukast | SNY Sanofi | Phase 2 | Active, not recruiting | 64 | Apr 1, 2027 | Registry ↗ |
| Oct 23, 2026 | Study to Assess the Plasma Concentration of Rilzabrutinib Given as a Tablet to Adult Participants W… NCT07853131 · Renal Impairment, Healthy Volunteers rilzabrutinib | SNY Sanofi | Phase 1 | Recruiting | 16 | Apr 21, 2027 | Registry ↗ |
The newest 50 items, most recent first. Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 10:34 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances